Bloomberg reports that Johnson & Johnson (JNJ +3.5%) is closing in on a deal with Britain's EUSA Pharma to sell Sylvant (siltuximab), an IL-6 inhibitor used to treat a rare lymph node disorder called Castleman disease. People close to the matter say the asset could fetch more than $100M.

Shares are up after the company reported Q2 results before the open.

READ FULL ARTICLE HERE